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Idiopathic generalized epilepsy (IGE) is a complex disease with high heritability, but little is known about its genetic architecture.
Rare copy-number variants have been found to explain nearly 3% of individuals with IGE; however, it remains unclear whether variants
withmoderate effect size and frequencies belowwhat are reliably detected with genome-wide association studies contribute significantly
to disease risk. In this study, we compare the exome sequences of 118 individuals with IGE and 242 controls of European ancestry by
using next-generation sequencing. The exome-sequenced epilepsy cases include study subjects with two forms of IGE, including
juvenile myoclonic epilepsy (n ¼ 93) and absence epilepsy (n ¼ 25). However, our discovery strategy did not assume common genetic
control between the subtypes of IGE considered. In the sequence data, as expected, no variants were significantly associated with the
IGE phenotype or more specific IGE diagnoses. We then selected 3,897 candidate epilepsy-susceptibility variants from the sequence
data and genotyped them in a larger set of 878 individuals with IGE and 1,830 controls. Again, no variant achieved statistical sig-
nificance. However, 1,935 variants were observed exclusively in cases either as heterozygous or homozygous genotypes. It is likely
that this set of variants includes real risk factors. The lack of significant association evidence of single variants with disease in this
two-stage approach emphasizes the high genetic heterogeneity of epilepsy disorders, suggests that the impact of any individual
single-nucleotide variant in this disease is small, and indicates that gene-based approaches might be more successful for future
sequencing studies of epilepsy predisposition.Introduction
In the past decade, there have been extensive efforts to
identify the genetic basis of common, complex human
disease. Until recently, this effort has focused primarily
on common variants with the use of genome-wide associ-
ation studies. Although a number of important gene
discoveries have emerged from this work, most of the iden-
tified variants have only a small effect on disease risk,
particularly of neuropsychiatric diseases.1 Recently,
however, studies have demonstrated that rare copy-
number variants (CNVs) contribute to the risk of devel-
oping neurological, psychiatric, and developmental
disorders.2–10 These findings implicate specific risk loci in
these diseases and also support the role of rare variation
in the genetic architecture of neuropsychiatric diseases.1Center for Human Genome Variation, Duke University School of Medicine
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ever, distinguishing the disease-causing variants from the
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found in each human genome presents a considerable
challenge. Although the optimum NGS study design for
identifying causal genetic loci in complex disease will
evolve as we expand our knowledge of the underlying
genetic architecture, NGS studies evaluating the role of
rare variants in complex diseases at this stage include two
broadly defined approaches: (1) variant-based assessments
for exploring the role of individual variants that have a rela-
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Figure 1. Overview of the Study DesignIn this study, we test the first approach and report on the
results of a NGS study of individuals with idiopathic gener-
alized epilepsy (IGE [MIM 600669], also known as genetic
generalized epilepsy), one of themost heritable subtypes of
common epilepsy.11,12Subjects and Methods
Study Population
IGE-affected subjects evaluated in this study were largely recruited
through the Epilepsy Genetics (EPIGEN) Consortium. Across
EPIGEN, subjects are recruited and enrolled by physicians during
routine clinical visits across five clinical sites: Erasme Hospital
and Universitair Ziekenhuis Gasthuisberg (Belgium), Duke
University Medical Center (United States), Beaumont Hospital
(Ireland), and the National Hospital for Neurology and Neurosur-
gery (England). Detailed phenotypic information is collected at
the time of enrollment and put into a database in a deidentified
manner for the facilitation of genetic association studies. Clinical
information is updated periodically when the individual returns
to the clinic for routine care and treatment. From the database
information, we selected 118 unrelated individuals of European
ancestry for the exome-sequencing phase of the study, and these
included 93 subjects with a diagnosis of juvenile myoclonic
epilepsy (JME [MIM 254770]) and 25 with a diagnosis of absence
epilepsy (AE [MIM 607631 and MIM 600131]). For follow-up
genotyping of candidate variants, we identified an additional294 The American Journal of Human Genetics 91, 293–302, August 10, 2012578 EPIGEN IGE-affected individuals
without restricting to particular ethnic-
ities, 181 DNA samples (of European
ancestry) obtained from the Coriell Cell
Repository (National Institute of Neuro-
logical Disease and Stroke epilepsy
collection), and eight additional unrelated
individuals with IGE (contributed by
James McNamara and Ruth Ottman). All
subjects selected for this study had clinical
and electroencephalographical character-
istics meeting the 1989 International
League against Epilepsy syndrome defini-
tions13 for childhood AE (MIM 600131),
juvenile AE (MIM 607631), JME (MIM
254770), or other unspecified forms of
IGE (MIM 600669). The full cohort of
885 IGE-affected individuals, either exome
sequenced or genotyped, included 131
individuals with a diagnosis of AE and
288 individuals with a diagnosis of JME.
Diagnoses were assigned by the treating
physician at each site. Approximately
90% of this follow-up IGE cohort was of
European ancestry.
Exome- or whole-genome-sequenced
controls consisted of a group of 242 indi-
viduals who were sequenced as part of
other NGS studies being carried out in
the Center for Human Genome Variation(Duke University). All 242 controls were of European ancestry
and were not enriched for epilepsy or other neuropsychiatric
phenotypes. Controls used for follow-up genotyping consisted of
an additional 1,780 subjects who were not enriched for neuropsy-
chiatric phenotypes and who were from the Genetics of Memory
and Epilepsy cohort collected in the Center for Human Genome
Variation, the Murdock Research Institute cohort, the Center
for HIV/AIDS Vaccine Immunology progression cohort, or the
high-risk seronegative HIV cohort. Approximately 65% of this
follow-up control cohort was of European ancestry. We note that
controls were matched for broad ancestral group (European) only.
This study was carried out in compliance with the institutional
review board at Duke University and the relevant ethics boards at
the collection sites. Informed consent was obtained from all study
participants or their legal guardians.
Study Design and Methods
In this study, we used a two-stage discovery approach that first em-
ployed exome sequencing in a series of IGE-affected individuals
and a subsequent large-scale follow-up genotyping of identified
candidate variants in a larger cohort of IGE-affected subjects and
controls (Figure 1).
Exome Sequencing, Alignment, and Variant Calling
Samples were either exome sequenced with Agilent’s All Exon
(37 Mb or 50 Mb) capture or whole-genome sequenced (n ¼ 51
controls) on Illumina GAIIx or HiSeq 2000 machines in the
Genomic Analysis Facility within the Center for Human Genome
Variation. Only the regions targeted on the 37 Mb or 50 Mb
Agilent All Exon platform were interrogated from the whole-
genome-sequenced samples. Sequencingwas performed according
to standard protocols. The targeted exonic regions of all sequenced
samples were sequenced to an average coverage of 64.33 5 13,
which translated to at least 53 coverage of approximately 86%
of the Human Genome Organization (HUGO)-defined protein-
coding regions in each subject. Paired-end reads were aligned to
the human reference genome (National Center for Biotechnology
Information Build 36) with Burrows-Wheeler Aligner software.14
Variant calling was performed with SAMtools software.15 Sequen-
ceVariantAnalyzer (SVA)16 was used for annotating variants iden-
tified from the sequence data (Ensembl 50_36l). This software
provides each variant with a genomic context (nonsynonymous
or splice-site coding, gene name, transcript, associated Gene
Ontology term, etc.).16 Association Tests for Annotated Variants
(ATAV) software was used for performing Fisher’s exact tests for
the comparison of the frequencies of variants identified from the
sequence data between cases and controls so that candidate vari-
ants for follow-up genotyping could be selected.
Identifying Candidate Variants from the Sequence Data
Variants for follow-up genotyping were selected on the basis of
variant-call quality, association evidence, and functional annota-
tion. We first isolated variants with a minor allele frequency
(MAF) of less than 5% in the control population in transcripts en-
coding a HUGO protein-coding gene, and only those predicted to
affect the protein-coding sequence (these included missense vari-
ants, nonsense variants, and single-nucleotide variants [SNVs]
residing in the highly conserved essential splice-site region—two
base pairs into an intron or one base pair into the exon at the
intron-exon junction). We then eliminated autosomal variants
that were out of Hardy-Weinberg equilibrium in controls
(p < 0.001), X chromosome variants that were out of Hardy-Wein-
berg equilibrium in females only (p < 0.001), sex-chromosome
variants called as heterozygotes in males, and variants with less
than 103 coverage inmore than 50%of sequenced subjects. These
quality-control steps left us with a set of high-quality variants that
were annotated as functional.
We then selected the subset of variants that were statistically
significantly enriched in cases (uncorrected p< 0.05, Fisher’s exact
test, allelic or recessive model, GROUP 1) and those with alleles or
genotypes exclusive to cases (GROUP 2) if they satisfied at least
one of the following selection criteria: (1) the variant genotype
was observed inmore than one individual with IGE, (2) the variant
was located in a region known to harbor pathogenic CNVs impli-
cated in neuropsychiatric disease, or (3) for variants with geno-
types observed in one case only, the variant met more stringent
criteria for functional effect, i.e., variants that were predicted to
disrupt an essential splice site, variants that targeted the transcript
for nonsense-mediated decay, and nonsynonymous variants pre-
dicted by Polyphen-217 to change protein function with high
confidence (‘‘probably damaging’’). SNVs composing GROUP 2
were also screened in an additional 296 sequenced controls of
other ethnicities (non-European ancestry) and were eliminated if
the genotype was observed.
Follow-Up Genotyping
Candidate variants were genotyped in additional cases and
controls with a custom designed iSelect genotyping chip (Illu-
mina). Of the 3,897 selected variants, 3,626 met the design
standards, permitting them to be included on the custom-
designed chip. Variants were genotyped in 878 IGE cases and
1,830 controls, including 111 of the 118 originally sequenced
cases and 50 of the 242 originally sequenced controls. In a separateThe Americeffort to identify susceptibility variants in schizophrenia (see Need
et al.18 in this issue of AJHG) and to assess phenotypic specificity
of the candidate epilepsy-susceptibility variants being evaluated,
we also included individuals with schizophrenia (MIM 181500)
in this follow-up genotyping study. After genotyping, the raw
data from the custom genotyping chip were evaluated with Illumi-
na’s GenomeStudio software. Any samples with a call rate below
0.95 were excluded from analysis. Several additional quality-
control steps were also taken for ensuring genotyping accuracy.
First, genders determined from genotyping were compared to
the record of sample genders. Samples with discordant gender calls
were excluded from further analysis. Next, genotype concordance
was checked for all samples that had been exome or whole-
genome sequenced. Any variant that had discordant calls between
the genotyping and sequencing data set and that could not be
reconciled with inspection of the genotyping or sequencing data
was excluded from further analysis. Finally, for subjects who had
been previously genotyped on an Illumina genome-wide genotyp-
ing chip, we compared the genotyping calls of a set of 170 variants
that were genotyped on both platforms and removed samples
with <95% concordance.
Candidate variants that were absent in the control population
were also evaluated in a cohort of ~5,400 samples exome
sequenced as part of the National Heart, Lung, and Blood Institute
(NHLBI) Grand Opportunity (GO) Exome Sequencing Project
(ESP) for the identification of genes contributing to heart, lung,
and blood disorders (Exome Variant Server [EVS], NHLBI ESP, Seat-
tle, WA). In order for a variant to be called present or absent in
a study sample, the coverage of the site was required to be at least
103 and any variant had to have a quality score of at least 30.
Association Testing
PLINK19 was used for performing logistic regression (allelic and
recessivemodels) on variants genotyped in the follow-up genotyp-
ing phase of the study (iSelect genotyping) for the identification of
variants enriched more in cases than in controls. Genome-wide-
association chip data (Illumina) were available on a subset of the
genotyped samples, which permitted the calculation of eigenvec-
tors so that population substructure in the logistic regression
could be corrected for according to the Eigenstrat method.20
Association testing for variants residing on the X chromosome
was performed in females only.Results
Exome Sequencing
After exome sequencing, alignment, and a series of quality-
control steps, we isolated 97,242 nonsense, missense, or
essential splice-site SNVs that were in transcripts encoding
a HUGO-defined protein-coding gene and that had a
control MAF of less than 5% from the variant profiles iden-
tified in the 118 IGE cases and 242 controls. A total of
9,987 SNVs were removed as a result of inconsistency
with Hardy-Weinberg equilibrium in controls or exces-
sively high missingness (i.e., insufficiently covered for
accurate variant calling), leaving us with 87,255 high-
quality functional variants with an estimated population
frequency of less than 5%. We performed logistic regres-
sions by using both allelic and recessivemodels to compare
the frequencies of variants in the cases and controls. Given
the number of variants tested and the sample size, we hadan Journal of Human Genetics 91, 293–302, August 10, 2012 295
Figure 2. Power for Detecting an Epilepsy-Susceptibility Variant
in This Study
The detectable relative risk of an IGE-susceptibility variant across
a range of MAFs in the sequencing phase of this study (blue line)
is compared to that of the follow-up genotyping phase of
this study (red line). To be significant, associations must have a
p value below 6 3 107, which is equivalent to p < 0.05 when
we correct for all 87,255 high-quality, functional variants that
were annotated as functional and had a control MAF < 5% in
the sequencing study. Power calculations were performed with
the CaTS-Power Calculator.21little power to achieve formal significance unless risk
alleles were common and/or of major effect (Figure 2).
Not surprisingly, there were no significant findings after
correction for the 87,255 single-variant association tests
performed (p < 6 3 1007). However, by targeting the
subset of variants showing nominal significance in the
sequence data in a follow-up cohort of 878 cases and
1,830 controls, we had power to detect variants over
a much broader range of parameters (Figure 2). Hence, all
candidate IGE-susceptibility variants selected from the
exome-sequencing data on the basis of the criteria defined
in the Subjects and Methods section were then taken
forward for genotyping in the follow-up cohort.
Importantly, we note that no correction was made for
population substructure when we selected variants from
the sequence data for follow-up genotyping. Because we
used a very liberal threshold for inclusion of variants, the
impact that not controlling for stratification has on power
should be modest. Furthermore, these variants would
subsequently be analyzed in further samples where
a correction for population stratification was incorporated
(see Subjects and Methods).
Because this selectionof candidate variants included vari-
ants with very modest statistical enrichment or exclusive
presence in IGE cases (which could occur if the variant is a
risk factor for JME, AE, or both [or neither]), we emphasize
that this study design does not presume that the genetic
control is constant across all syndromes composing IGE.
Follow-Up Genotyping of Candidate Variants
Variant Validation
In total, 3,897 variants met the defined candidate-variant
criteria. Because the reference-mapping approaches used296 The American Journal of Human Genetics 91, 293–302, August 1in this analysis have been shown to generate false posi-
tives,22 we calculated validation rates among our selected
variants to evaluate the extent to which this occurred.
On average, 96% of SNVs selected from the exome-
sequencing study were confirmed in the iSelect follow-up
analysis to be present in the variant carrier or in another
subject analyzed in this study. We did not see differences
in validation rates between functional groups, as previ-
ously reported for more common variants,22 which is
most likely due to the highly stringent quality control
used in this analysis, as well as the fact that the majority
of the variants selected for follow-up analysis were
predicted to be deleterious.
Association Testing
Of the 3,897 selected variants, 3,349 were successfully
genotyped on a custom-designed iSelect genotyping chip
(Illumina) and passed the defined quality-control criteria.
The 3,349 SNVs were first tested for association with the
IGE phenotype in the larger cohort. In a subset of samples
(460 IGE cases versus 814 controls), we applied Eigenstrat
axes to control for stratification.20 The eigenvectors gener-
ated from the genome-wide genotyping data were incorpo-
rated as covariates into the logistic regression comparing
the genotype frequency of the candidate susceptibility
variants in cases and controls. The quantile-quantile plot
suggests that population substructure has been adequately
corrected for in this analysis (Figure 3). Using a Bonferonni
correction for all rare, functionally annotated variants
identified in the exome-sequencing study (n ¼ 87,255),
we found that no variants had a corrected p value below
0.05. Table 1 provides a list of the ten lowest p values
showing enrichment in IGE cases under an allelic model.
Among these, the most significantly enriched is a nonsy-
nonymous variant (c.103C>G [p.Pro35Ala]; Ensembl
accession number ENST00000322805 and RefSeq acces-
sion number NM_001191323) located in GREM1. This
gene belongs to a family of bone morphogenetic protein
antagonists and is believed to play a role in organogenesis
and tissue differentiation.23 This GREM1 SNV is located
within 100 kb of the 15q13.3 region that was recently
found to harbor large genomic deletions that associate
with epilepsy, schizophrenia (MIM 181500), and autism
(MIM 209850).5,9,24,25 No trend associations (uncorrected
p < 0.05) were detected with a recessive model.
Likewise, subanalyses of individuals with a diagnosis of
AE (n ¼ 61) and JME (n ¼ 173) revealed no study-wide
significant associations.
Evaluation of Variants with Alleles or Genotypes Exclusive
to Cases
We next evaluated the 1,863 SNVs for which the variant
allele continued to be exclusively present in cases after
follow-up genotyping (Table S1, available online). We
examined the frequency of these variants in an additional
~5,400 subjects who had their exomes sequenced as part of
the NHLBI GO ESP. A total of 1,289 variants remained
absent in the NHLBI control population, and 23 were not
sufficiently covered for the evaluation of frequency (noted0, 2012
Figure 3. Quantile-Quantile Plot Shows No Evidence of Popula-
tion Stratification
A quantile-quantile plot of transformed p values (black dots)
against the expected transformed p values for variants with at least
six alleles represented in the study population. The red line indi-
cates the expectation under the null model of no effect on risk.
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.in Table S1). Among these 1,289 rare candidate variants is
a missense mutation (c.620C>T [p.Ala207Val]; Ensembl
ENST00000396881) in PSME2 (MIM 602161); this muta-
tion was observed in five unrelated IGE cases (Table 2).
PSME2 encodes the proteasome activator complex subunit
2 and is involved in antigen processing and the assembly
of the immunoproteasome.26 The encoded protein has
no reported role in epilepsy pathophysiology; however,
expression of the gene has been shown to be upregulated
in mesial temporal-lobe epilepsy.27
In addition, among this set of candidate variants are
two heterozygous variants—c.1205A>G (p.Asn402Ser)
(Ensembl ENST00000303498) in BTD (MIM 609019) and
c.740C>G (p.Pro247Arg) (Ensembl ENST00000244546
and RefSeq NM_000060) in PEX6 (MIM 601498)—in genes
responsible for severe, recessive neurological disorders that
usually include seizures (e.g., biotinidase deficiency [MIM
253260] and Zellweger syndrome [MIM 214100]). It is
possible that a mutation in one copy of these genes might
lead to less-severe phenotypes such as epilepsy alone.
Next, we evaluated SNVs that were found in the homo-
zygous state exclusively in individuals with IGE (n ¼ 72,
Table 3 and Table S2). No homozygotes were observed in
the EVS for 36 of these variants, and eight were not
sequenced in the NHLBI cohort (Table S2). One variant
in AGPAT3, encoding an acyltransferase involved in the
phospholipid biosynthetic pathway,28 was homozygous
in three unrelated IGE cases. This gene does not have
any known direct involvement in epilepsy.
In the interest of evaluating the phenotypic specificity of
these candidate epilepsy-susceptibility variants, we have
provided the number of JME and AE carriers in Tables S2
and S3. Even though we considered these to be very
specific phenotypes, we still failed to identify study-wide
significant associations.The American Journal of Human Genetics 91, 293–302, August 10, 2012 297
Table 2. SNVs Present in at Least Three IGE-Affected Individuals, Absent in the Control Population Evaluated in This Study, and Absent from the NHLBI Exome-Sequenced Cohort
Variant
(chr_hg18
position_ allele) Gene
MIM
Number
Transcript
(Ensembl 50_36l)
Transcript
(RefSeq)
Position of
Sequence and
Amino Acid Change
Annotated
Function
IGE Countsa
(Hom/Het/
Reference)
Control Countsa
(Hom/Het/
Reference) p Valueb
MAF (%)/Number
of Subjects (NHLBI
Cohort)
14_23682683_A PSME2 602161 ENST00000396881  c.620C>T (p.Ala207Val) NS 0/5/874 0/0/2,021 0.003 0/5,379
7_30760037_A INMT 604854 ENST00000013222 NM_006774.4 c.320G>A (p.Trp107*) SG 0/3/875 0/0/2,005 0.028 0/5,379
7_150410267_T TMUB1  ENST00000297533 NM_031434.3 c.317G>A (p.Arg106Gln) NS 0/3/876 0/0/2,011 0.028 0/5,379
2_235615236_G SH3BP4 605611 ENST00000322950  c.865C>G (p.Pro289Ala) NS 0/3/875 0/0/2,020 0.028 0/5,378
3_46425043_A CCRL2 608379 ENST00000399036 NM_003965.4 c.469G>A (p.Val157Ile) NS 0/3/875 0/0/1,981 0.028 0/4,927
6_43054127_C PEX6 601498 ENST00000244546  c.740C>G (p.Pro247Arg) NS 0/3/875 0/0/2,022 0.029 0/5,379
3_135148919_T SLCO2A1 601460 ENST00000310926 NM_005630.2 c.1166G>A (p.Arg389His) NS 0/3/875 0/0/2,022 0.029 0/5,379
3_15661572_G BTD 609019 ENST00000303498 NM_000060.2 c.1205A>G (p.Asn402Ser) NS 0/3/875 0/0/2,022 0.029 0/5,379
13_47884428_T P2RY5 609239 ENST00000345941 NM_001162498.1 c.133G>A (p.Val45Ile) NS 0/3/875 0/0/2,022 0.029 0/5,379
5_153746175_G GALNT10 608043 ENST00000377661  c.862T>G (p.Ser288Ala) NS 0/3/876 0/0/2,022 0.029 0/5,379
4_157080116_T CTSO 600550 ENST00000281527  c.409G>A (p.Val137Met) NS 0/3/876 0/0/2,022 0.029 0/5,379
19_45206312_A ZNF546  ENST00000347077 NM_178544.3 c.394G>A (p.Asp132Asn) NS 0/3/875 0/0/2,022 0.029 0/5,379
A full list of variants with IGE-specific alleles is provided in Table S2. The following abbreviations are used: IGE, idiopathic generalized epilepsy; MAF, minor allele frequency; NS, nonsynonymous; and SG, stop gained.
aCounts include both sequenced and iSelect genotyped samples.
bFisher’s exact test comparing carriers to noncarriers in the study cohort only (i.e., excluding NHLBI exome-sequenced samples).
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The AmericPathway Analysis of Genes Harboring Candidate Epilepsy-
Susceptibility Variants
Weperformed a pathway analysis including all 1,183 genes
harboring a SNV with a genotype exclusive to individuals
with IGE, JME, or AE (and also absent from the NHLBI
control cohort) by using the Reactome software.29 After
applying a Bonferroni correction for the number of tests
performed, we observed no pathways significantly over-
represented in any phenotypic group (detailed pathway
results for genes associated with the IGE phenotype are
provided in Table S3).Discussion
In this study, we evaluated 3,349 candidate epilepsy-
susceptibility variants (identified in an exome-sequencing
study of 118 IGE cases) in a larger cohort of 878 cases and
1,830 controls and did not find any variants with statisti-
cally significant associations. One possible explanation
for the lack of significant findings is that epilepsy-suscepti-
bility variants are sufficiently rare that each one accounts
for only a small fraction of individuals with epilepsy.
This finding is consistent with that observed with CNVs
in epilepsy disorders in that deletions at 15q13.3 and
16p13.11—despite the fact that they explain a significant
proportion of cases—are very rare when one considers
each identical-by-descent deletion event.3,4,9,24,30 If this
supposition is true, then among the list of candidate
susceptibility variants identified in this sequencing study
is a set of very rare disease-causing variants. Of the 3,349
variants studied, 1,325 variants or homozygous genotypes,
including 103 that were observed in additional IGE cases in
the follow-up phase and 118 that are located in genes
previously implicated in linkage studies of individuals
with IGE, remain exclusively present in cases (they are
absent from both the current study control cohort and
the NHLBI cohort) (Tables S1 and S4).
Under the assumption that some of these candidate rare
variants are causal (Tables S2 and S3), we can use our data
to estimate the extent of genetic heterogeneity in IGE. The
variant observed most commonly in the IGE cases studied
here (c.620C>T [p.Ala207Val] in PSME2; 14_23682683_A;
Ensembl ENST00000396881; Table 2) appears to account
for approximately 0.6% of the studied cases, assuming
that the variant ultimately proves to be causal. When we
consider variants with genotypes exclusively seen in indi-
viduals with JME and absent in all control populations and
study participants with a diagnosis of AE or schizophrenia,
no single variant identified in our study can explain more
than 1% of individuals with JME. Likewise, no single
variant can explain more than 1.5% of AE cases evaluated
in this study. Collectively, this suggests that no single-base
substitution affecting the protein (represented in the
exome data) causes epilepsy in a large percentage of IGE
cases (or JME or AE cases), a finding consistentwith amodel
of high genetic heterogeneity, probably including bothan Journal of Human Genetics 91, 293–302, August 10, 2012 299
locus and allelic heterogeneity. It is also likely that gene-
level association analysesmight effectively guide us toward
epilepsy-susceptibility genes that would be readily missed
in the single-variant analyses in this study as a result of
allelic heterogeneity. Consistent with this hypothesis, we
note that many of the identified case-only variants (absent
in both this study cohort and the NHLBI cohort) reside in
the same gene (Tables S1 and S2). In total, 115 genes,
including seven genes with a rare variant in more than
three IGE-affected individuals and two genes with a rare
variant in six IGE study subjects, have multiple rare vari-
ants in IGE cases only (Table S5). Assuming that allelic
heterogeneity might contribute in part to the overall
genetic heterogeneity associated with IGE, future studies
should focus on gene-level association analyses.
It is possible that beyond locus and allelic heterogeneity,
other multilocus models might account for the negative
results we observed in our study. Although oligogenic,
polygenic, or epistatic modes of disease-risk inheritance
are possible, statistical proof for these multivariant models
has to withstand very high thresholds of multiple testing
to be detected in NGS studies. It is likely that if these
models account for some fraction of disease risk, they
will only be secondarily identified in NGS studies if
marginal effects of single variants can be detected in very
large sample sizes.
Although it does not yet provide definitive evidence of
specific risk factors, this work makes a number of impor-
tant contributions to epilepsy genetics. First and most
fundamentally, this work strongly suggests that moder-
ately rare variants with intermediate effects (‘‘goldilocks
alleles’’31) do not play a major role in the risk of IGE. In
this study, we had 80% power to detect a putatively func-
tional coding SNV with a frequency of 0.5% and a relative
risk of 5.4. However, power decreases as the variants
become rarer or carry less relative risk. Although the power
for obtaining secure evidence for an association of any
individual variant with MAFs between 0.1% and 0.5% in
this study is only modest (for example, ~10% power for de-
tecting a SNV with a MAF of 0.3% and a relative risk of 5),
we would have detected some of them here if there were
many such IGE-susceptibility alleles in the human gene
pool. This suggests that discovery will require designs
that can provide evidence of variants that are outside
this range in terms of either effect size or allele frequency
or both.
Second, this study provides a candidate gene list that is
likely to include real IGE risk factors. Interestingly, the
pathway analysis of the genes harboring candidate
epilepsy-susceptibility variants revealed no evidence of
enrichment of genes encoding ion channels or ion-
channel modifiers (Table S3). This lack of enrichment of
protein-disrupting ion-channel mutations in individuals
with epilepsy is consistent with what was observed by Klas-
sen et al.32 Collectively, these findings suggest that the
pathophysiology governing epilepsy might be far more
complex than simply a disorder of disrupted ion channels300 The American Journal of Human Genetics 91, 293–302, August 1(‘‘channelopathy’’), as was suggested by early studies of
Mendelian epilepsies.
Third, the results of this study provide a benchmark
against which researchers can compare small studies that
are likely to emerge in the near future and claim evidence
of pathogenicity. Given the near comprehensive assess-
ment of coding variation reported here, pathogenicity
claims based on small discovery samples need to be treated
with caution. Finally, under the assumption that some of
the variants reported here as exclusive to epilepsy cases
are real risk factors, these results give us the opportunity
to estimate how many samples will be needed for statisti-
cally significant evidence of any single associated variant.
By assuming that the frequency of the risk alleles observed
in our follow-up sample is correct and by simply scaling up
the sample sizes, we can determine at what point we
expect to achieve p < 6 3 107, which would be suffi-
ciently low to account for the testing of the >100,000
variants identified in the sequenced cohort. In this study,
candidate variants were seen at a frequency range of
0.06%–0.3% among study subjects with IGE. If these
frequencies are consistent in follow-up cohorts, we would
need equivalently sized case and control cohorts of
between 2,000 and 6,000 individuals each to prove the
association of variants seen at a frequency of 0.1%–0.5%
of IGE cases. Importantly, for variants that are seen in
only one case (those that have a frequency of approxi-
mately 0.06%), proving pathogenicity is virtually out of
reach even with large sample sizes; such variants will prob-
ably only be securely implicated through gene-based asso-
ciation analyses in large sample sizes and, where available,
cosegregation analyses within multiplex families.33Supplemental Data
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